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Introduction
Two recent systematic reviews that evaluated intensive 
insulin therapy (IIT) in critically ill patients grouped the 
included randomized controlled trials (RCTs) by type of 
intensive care unit (ICU): surgical versus medical versus 
mixed medical–surgical [1,2]. Both reviews found no 
mortality reduction among all critically ill patients. Th  e 
more recent review by Griesdale and colleagues, however, 
found that IIT reduced mortality in patients admitted to 
surgical ICUs, but not in patients admitted to medical 
ICUs or mixed medical–surgical ICUs [2]. Potential 
explanations to support the beneﬁ  cial  eﬀ   ects of IIT 
among critically ill surgical patients were proposed in the 
accompanying editorial: a greater use of central and 
arterial lines in surgical ICUs, which allows for more 
accurate monitoring and correc  tion of blood glucose; 
acute hyperglycemia in surgical patients, who are more 
likely to beneﬁ  t from correction than medical patients 
with chronic elevations and adap  tive responses; and 
better achievement of target glucose levels in surgical 
ICU studies compared with medical ICU or mixed ICU 
studies [3]. In contrast to the ﬁ  nding of the most recent 
review, however, the large NICE-SUGAR RCT enrolling 
over 6,000 critically ill patients suggested increased 
mortality both overall and among the subgroup of surgical 
patients [4]. (Th   is largest trial to date was included in the 
most recent review but was analyzed among the mixed 
medical–surgical ICU group of trials [2].)
Th  ese contrasting results between the meta-analyses 
[1,2] and the most recent trial [4] may stem from sensi-
tivity of the meta-analytic results to methodologic deci-
sions. In particular, the decision to group trials by type 
of ICU rather than by type of patient may not be 
intuitive for clinicians, for whom the important 
question is whether IIT saves lives in critically ill 
surgical patients regardless of the type of ICU in which 
they are treated, which depends on hospital 
organization. Th  e objective of the present viewpoint 
article was therefore to determine whether IIT has a 
diﬀ  erential  eﬀ   ect in surgical compared with medical 
critically ill patients by incorporating all available 
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mixed ICU trials.
Categorizing surgical and medical subgroups by 
type of patient rather than type of ICU
We considered all trials of IIT included in the two recent 
systematic reviews [1,2]. Our primary analysis used the 
RCTs included in the more recent review [2], which 
found diﬀ  erential eﬀ  ects between patients admitted to 
medical ICUs and surgical ICUs. Th  e review’s primary 
outcome was 90-day mortality – or, if not available, then 
hospital mortality, 28-day mortality, or ICU mortality (in 
descending order of preference; two trials reported only 
6-month mortality). Since both reviews were published 
recently, we did not update the literature search; for 
included conference abstracts, however, we searched for 
and used data from subsequently published full reports. 
For trials conducted in mixed ICUs, we extracted mor-
tality data separately for surgical and medical sub groups, 
and contacted authors to request subgroup data when 
not reported in the original publication. We grouped 
these outcomes with data reported in trials conducted 
exclusively in surgical ICUs and in medical ICUs. We 
used the categorization of surgical patients and medical 
patients by the authors of the mixed ICU RCTs and 
assumed that trials conducted in surgical ICUs and 
medical ICUs included exclusively surgical patients and 
medical patients, respectively. For one RCT, classiﬁ  ed 
diﬀ   erently in the two systematic reviews [1,2], we 
conﬁ  rmed with the study authors that the trial was con-
duc  ted in a mixed ICU [5]. For our primary analysis, we 
constructed a surgical subgroup including trial-level data 
from the surgical ICU trials and surgical group-level data 
from the mixed ICU trials. We used a similar approach 
for the medical subgroup.
Mortality data in each subgroup were pooled using 
random-eﬀ   ects models, which incorporate between-
study heterogeneity (Review Manager; Cochrane Colla-
bora  tion, Oxford, UK), expressed as risk ratios (RRs) with 
95% conﬁ  dence intervals (CIs). Pooled RRs in the surgical 
and medical subgroups were compared using a z test, 
with a signiﬁ  cance level of 0.05. Statistical between-trial 
heterogeneity within each subgroup was assessed using 
the I2 measure with 95% CIs [6].
We conducted three sensitivity analyses. Th  e ﬁ  rst 
included only trials conducted in mixed ICUs that enrolled 
both surgical patients and medical patients. Th  is  analysis 
addresses the possibility that diﬀ   erences between trials 
other than patient population could explain diﬀ  erential 
eﬀ  ects.  Th  e second analysis included trials in the ﬁ  rst 
systematic review by Wiener and colleagues [1] that were 
excluded by the more recent review by Griesdale and 
colleagues [2]. Th   e third analysis included only trials that 
actually achieved tight glucose control, as deﬁ  ned by a 
mean blood glucose of 4.4 to 6.1 mM (the most commonly 
targeted range) in the intervention group.
Of the 16 RCTs conducted in mixed ICUs [4,5,7-20], 
mortality data for surgical and medical subgroups were 
available for 14 RCTs [4,5,7-18] and were unavailable for 
one RCT [19] after author contact; we were unable to 
contact the aut  hors of one study [20]. Th  ese 14 RCTs 
provided data for 9,935/10,206 (97%) of patients random-
ized in mixed ICU trials [4,5,7-18]. Th  ese data were 
combined with the ﬁ  ve RCTs (1,972 patients) conducted 
exclusively in surgical ICUs [21-25] and the ﬁ  ve RCTs 
(1,371 patients) in medical ICUs [26-30] included in the 
most recent review. For each included trial, Table  1 
presents the target and mean achieved blood glucose 
values for both treatment groups and the mortality time 
point analyzed.
Meta-analyses showed no eﬀ  ect of IIT in the subgroups 
of surgical patients (RR = 0.85, 95% CI = 0.69 to 1.04, 
P = 0  .11) or of medical patients (RR = 1.02, 95% CI = 0.95 
to 1.09, P = 0.61) (Figure 1 and Table 2). Th  ere was no 
evidence of a diﬀ  erential  eﬀ   ect between subgroups 
(P = 0.10). Th   ere was moderate statistical heterogeneity 
in the surgical subgroup (  I2 = 51%, 95% CI = 1 to 75%) but 
none in the medical subgroup (I2 = 0%, 95% CI = 0 to 
41%). Considering surgical patients, the eﬀ   ect of IIT 
appeared consistent in the subgroup of surgical ICU 
trials, in which the point estimate for I2  is 0%. However, 
the 95% conﬁ  dence interval of this estimate of hetero-
geneity (0 to 70%) is wide and similar to the I2 conﬁ  dence 
interval for both the surgical subgroup of the mixed ICU 
studies and the entire surgical patient population (see 
Figure 1a). Th  is suggests that substantial heterogeneity 
cannot be excluded [31], even in the subgroup of surgical 
ICU trials.
Results of sensitivity analyses were similar to those of 
the primary analysis (Table 2). First, the analysis res-
tricted to 12 mixed ICU trials enrolling both surgical and 
medical patients found RR = 0.98 (95% CI = 0.80 to 1.19, 
P = 0.82; I2 = 40%) in surgical patients and RR = 1.03 (95% 
CI = 0.94 to 1.13, P = 0.51; I2 = 8%) in medical patients 
(P = 0.66 for comparison of RRs). Second,   the analysis 
adding the results of the three surgical ICU trials [32-34] 
and the three medical ICU trials [35-37] included only in 
the earlier systematic review [1] found RR = 0.89 (95% CI = 
0.74 to 1.08, P = 0.24; I2 = 45%) in surgical patients and 
RR = 1.02 (95% CI = 0.96 to 1.09, P = 0.46; I2 = 0%) in 
medical patients (P = 0.18 for comparison of RRs). 
Finally, the analysis of   trials achieving tight glucose 
control (four out of eight surgical ICU trials, two out of 
eight medical ICU trials, and ﬁ  ve out of 14 mixed ICU 
trials) found RR =0.76 (95% CI = 0.57 to 1.01, P = 0.06; 
I2 = 10%) in surgical patients and RR = 1.04 (95% CI = 
0.71 to 1.53, P = 0.82; I2 = 7%) in medical patients 
(P  =  0.20 for comparison of RRs). Th  is last subgroup 
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[21] and excludes the six other largest trials (one in a 
medical ICU [27] and ﬁ  ve in mixed ICUs [4,11,12,16,17]) 
that targeted the same blood glucose range in the 
intervention group (4.4 to 6.1 mM) but achieved slightly 
higher mean values (6.2 to 6.6 mM). Although there was 
a nonsigniﬁ  cant trend to beneﬁ  t of IIT in the surgical 
subgroup considered in isolation for this sensitivity 
analysis, there is no evidence that the eﬀ  ect diﬀ  ered from 
medical patients.
Given this lack of diﬀ   erence between surgical and 
medical subgroups in any of the primary or secondary 
Table 1. Target and achieved blood glucose and mortality outcome time point by trial
  Intervention group  Control group 
    Glucose Mean  achieved  Glucose Mean  achieved  Mortality
    target glucose  target glucose  outcome
Study (mM)  (mM) (mM)  (mM) time  point
Studies included in the more recent systematic review [2]   
Surgical ICU studies         
  Van den Berghe and colleagues [21]  4.4 to 6.1  5.7  10.0 to 11.1  8.5  Hospital
  Grey and Perdrizet [22]  4.4 to 6.7  6.9  10.0 to 12.2  9.9  Hospital
  Bilotta and colleagues (SAH) [23]  4.4 to 6.7  5.0  <12.2  8.3  6-month
  He and colleagues [24]  4.4 to 8.3  6.7  10.0 to 11.1  10.0  Hospital
  Bilotta and colleagues (TBI) [25]  4.4 to 6.7  5.1  <12.2  8.2  6-month
Medical ICU studies         
  Bland and colleagues [26]  4.4 to 6.1  5.8  10.0 to 11.1  9.8  28-day
  Van den Berghe and colleagues [27]  4.4 to 6.1  6.2  10.0 to 11.1  8.5  90-day
  Walters and colleagues [28]  5.0 to 8.0  6.9  ≤15.0  8.1  30-day
  Oksanen and colleagues [29]  4.0 to 6.0  5.0  6.0 to 8.0  6.4  30-day
  Bruno and colleagues [30]  5.0 to 7.2  7.4  <11.1  10.6  90-day
Mixed medical–surgical ICU studies         
  Mitchell and colleagues [8]  4.4 to 6.1  5.4  10.0 to 11.1  7.9  Hospital
  Azevedo and colleagues [9]  4.4 to 6.7  7.4  <10.0  8.0  ICU
  Preiser and colleagues [11]  4.4 to 6.1  6.6  7.8 to 10.0  8.2  Hospital
  Brunkhorst and colleagues [12]  4.4 to 6.1  6.2  10.0 to 11.1  8.4  90-day
  Iapichino and colleagues [13]  4.4 to 6.1  6.1  10.0 to 11.1  9.1  90-day
  He and colleagues [14]  4.4 to 6.1  5.1  10.0 to 11.1  10.6  ICU
  Zhang and colleagues [15]  4.4 to 6.1  6.1  10.0 to 11.1  7.7  Hospital
  De La Rosa and colleagues [16]  4.4 to 6.1  6.5  10.0 to 11.1  8.2  Hospital
  Arabi and colleagues [17]  4.4 to 6.1  6.4  10.0 to 11.1  9.5  Hospital
  Mackenzie and colleagues [18]  4.0 to 6.0  7.0  <11.0  8.4  Hospital
  NICE-SUGAR [4]  4.5 to 6.0  6.4  <10.0  8.0  90-day
  Farah and colleagues [5]  6.1 to 7.8  7.9  7.8 to 11.1  9.7  28-day
  Yu and colleagues [7]  4.4 to 6.1  5.7  10.0 to 11.1  11.1  Hospital
  McMullin and colleagues [10]  5.0 to 7.0  7.1  8.0 to 10.0  9.4  Hospital
Additional studies included only in the earlier systematic review [1]   
Surgical ICU studies         
  Stecher and colleagues [32]  4.4 to 6.1  n/a  7.8 to 10.0  n/a  n/a
  Kia and colleagues [33]  4.2 to 6.4  6.0  10.0 to 11.1  8.0  90-day
  Chan and colleagues [34]  4.4 to 6.7  7.0  <11.1  9.3  Hospital
Medical ICU studies         
  Fernandez and colleagues [35]  4.4 to 6.1  6.7  <8.3  11.4  Hospital
  Davies and colleagues [36]  4.0 to 8.0  10.3  <10.0  10.7  Hospital
  Gray and colleagues [37]  4.0 to 7.0  6.3  <17.0  6.8  90-day
ICU, intensive care unit; n/a, not available; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury.
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Page 3 of 7Figure 1. Eff  ect of intensive insulin therapy on mortality in surgical and medical patients. A z test of interaction between the risk ratio (RR) 
for mortality in (A) all surgical patients and (B) all medical patients was not statistically signifi  cant (P = 0.10), indicating that treatment eff  ects did 
not diff  er between these two groups. This was also the case if one compares medical and surgical patients only within the same – that is, mixed 
intensive care unit (ICU) – trials (P = 0.66). Of the 14 trials conducted in mixed ICUs [4,5,7-18], one enrolled only surgical patients [7] and one 
enrolled only medical patients [10]. Preiser and colleagues’ article [11] is the full publication of the abstract included in the most recent review [2]. 
After accounting for readmissions, subgroup-specifi  c outcomes data were available for 991 out of 1,078 patients randomized. Compared with data 
presented in the most recent systematic review [2], subgroup-specifi  c outcomes data are complete for all other trials except for 1/535 patients with 
missing data in one trial [12]. CI, confi  dence interval; I2, percentage of total variation across studies due to between-study heterogeneity rather than 
chance; IIT, intensive insulin therapy; n/N = number of deaths/number of patients randomized; SAH, subarachnoid hemorrhage; TBI, traumatic brain 
injury.
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 Grey [22]                   4/34               6/27           2.57      0.53 [0.17, 1.69]        
 Bilotta [23] (SAH)          6/40               7/38           3.30      0.81 [0.30, 2.20]        
 He W [24]                   7/150              6/38           3.12      0.30 [0.11, 0.83]        
 Bilotta [25] (TBI)          5/48               6/49           2.73      0.85 [0.28, 2.60]        
Subtotal (95% CI)  23.09      0.64 [0.48, 0.84]
Test for Overall Effect:  p=0.001
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Surgical Subgroup in Mixed Medical-Surgical ICU Studies
 Brunkhorst [12]            49/135             45/147        11.25     1.19 [0.85, 1.65]        
 Iapichino [13]              3/15               8/19           2.64      0.48 [0.15, 1.49]        
 He ZY [14]                  7/31              15/35           4.97      0.53 [0.25, 1.12]        
 Zhang [15]                  1/152              4/152          0.82      0.25 [0.03, 2.21]        
 De La Rosa [16]            54/131             48/127         11.81      1.09 [0.81, 1.48]        
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 Bruno [30]                  2/31               0/15           0.05      2.50 [0.13, 49.05]       
Subtotal (95% CI)  22.48      0.96 [0.83, 1.10]
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 Mitchell [8]                7/23               3/20           0.31      2.03 [0.60, 6.82]        
 Azevedo [9]                28/99              25/100          2.15      1.13 [0.71, 1.80]        
 Preiser [11]               69/211             62/203          5.71      1.07 [0.81, 1.42]        
5 47 1 07 [0 80 1 44]
Medical Subgroup in Mixed Medical-Surgical ICU Studies
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 Iapichino [13]             11/30               5/26           0.55      1.91 [0.76, 4.77]        
 He ZY [14]                  9/27              14/29           1.08      0.69 [0.36, 1.33]        
 Zhang [15]                  3/16               2/18           0.17      1.69 [0.32, 8.85]        
 De La Rosa [16]            48/123             48/123          4.71      1.00 [0.73, 1.37]        
 Arabi [17]                 66/223             73/212          6.09      0.86 [0.65, 1.13]        
 Mackenzie [18]             26/62              36/68           3.38      0.79 [0.55, 1.15]        
 NICE-SUGAR [4]            557/1898           529/1891       45.50     1.05 [0.95, 1.16]        
 Farah [5]                  19/31              14/37           1.85      1.62 [0.98, 2.67]        
 McMullin [10]               6/11               4/9            0.56      1.23 [0.49, 3.04]        
Subtotal (95% CI)  77.52      1.04 [0.96, 1.12]
Test for Overall Effect:  p=0.38
Heterogeneity:  I2 = 1% (95% CI 0-57%)
898/2866 872/2876
100.00      1.02 [0.95, 1.09]
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1129/3549 1120/3564 Total Medical
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 Favours IIT  Favours control
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Friedrich et al. Critical Care 2010, 14:324 
http://ccforum.com/content/14/5/324
Page 4 of 7analyses, the best estimate of IIT eﬀ  ect in both sub  groups 
is the overall eﬀ  ect, which is nil (see Table 2).
Discussion and conclusions
Our analysis shows no eﬀ  ect of IIT in surgical or medical 
critically ill patients. We found moderate between-trial 
diﬀ  erences in the eﬀ  ect of IIT in the surgical subgroup, 
reﬂ  ecting the contrasting results of two trials enrolling 
the most surgical patients: the study by Van den Berghe 
and colleagues [21] and the NICE-SUGAR study [4]. As 
noted by other studies [1,2,21,38,39], multiple factors 
may have contributed to the positive result in the single-
center trial by Van den Berghe and colleagues that mainly 
enrolled cardiac surgery patients [21]: patient population 
(higher control group mortality than expected), local care 
practices (in particular, routine use of intravenous 
glucose and parenteral nutrition [40]), early stopping 
after an interim analysis showed beneﬁ  t, and a higher 
target glucose range in the control group compared with 
other trials.
Furthermore, our analysis reveals the variable 
deﬁ   nitions of surgical patients that may also have 
contributed to between-trial heterogeneity: some trials 
included only postoperative patients, while others also 
included patients who required ICU readmission from 
surgical wards or nonoperative patients with surgical 
diagnoses such as pancreatitis or trauma. Based on the 
available data, there does not appear to be any obvious 
subgroup of surgical patients that consistently beneﬁ  ts 
from IIT. Of the two trials conducted in patients after 
cardiac surgery, Van den Berghe and colleagues found a 
mortality beneﬁ  t [21], but the much smaller trial by Chan 
and colleagues did not [34]. Moreover, Van den Berghe 
and colleagues’ trial included patients who required ICU 
readmission from surgical wards in addition to 
immediately postoperative patients. Other trials classiﬁ  ed 
such patients as medical, and no trial suggested beneﬁ  t in 
medical patients. Furthermore, in the NICE-SUGAR 
trial, operative patients were deﬁ   ned as immediately 
postoperative ICU admissions – and this trial actually 
suggested harm in such patients [4].
In summary, we analyzed the eﬀ  ect of IIT in surgical 
patients, regardless of the type of ICU to which they were 
admitted, and found no eﬀ  ect on mortality – similar to 
the eﬀ   ect for critically ill medical patients and all 
critically ill patients combined [1,2]. We therefore do not 
recommend this intervention for critically ill surgical 
patients or critically ill medical patients. Further insights 
into the eﬀ  ects of this intervention in surgical patients 
may come from individual patient data meta-analyses, 
acknowledging the challenges of ensuring availability and 
comparability of data among trials and obtaining expert 
statistical support. Alternatively, future large multicenter 
RCTs in speciﬁ   c patient subgroups, such as cardiac 
surgical patients, may further reﬁ  ne our understanding of 
the role of IIT in the ICU.
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intensive care unit; IIT, intensive insulin therapy. aIncludes also mixed ICU trials for which separate surgical and medical subgroup data were not available [19,20]. 
bSurgical versus medical interaction. cSee also Figure 1.
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